Yildirim, GamzeSahli, EsraAlp, Mehmet Numan2024-11-072024-11-0720201300-06592147-2661https://doi.org/10.4274/tjo.galenos.2020.97415https://hdl.handle.net/11480/16076Objectives: To evaluate the effect of proptosis on choroidal thickness in patients with Graves' ophthalmopathy. Materials and Methods: Twenty-five eyes of 25 Graves' patients with proptosis, 25 eyes of 25 Graves' patients without proptosis, and 25 eyes of 25 healthy individuals were included in this prospective study. The subfoveal choroidal thickness and choroidal thicknesses at 6 points from the fovea at 500 mu m intervals were measured by Cirrus HD-OCT. All measurements were compared among the proptosis, non-proptosis, and control groups and the active, inactive, and control groups. Results: The mean subfoveal choroidal thickness in the proptosis group was 289.7 +/- 68.5 mu m, 322.5 +/- 55.8 mu m in the non-proptosis group, and 316.1 +/- 63.0 mu m in the control group. The mean nasal choroidal thickness was 260.5 +/- 63.5 mu m in the proptosis group, 293.9 +/- 57.9 mu m in the non-proptosis group, and 279.5 +/- 63.1 mu m in the control group. The mean temporal choroidal thickness was 261.8 +/- 60.9 mu m in the proptosis group, 289.0 +/- 51.8 mu m in the non-proptosis group, and 287.8 +/- 56.2 mu m in the control group. Mean choroidal thickness was 264.7 +/- 58.5 mu m in the proptosis group, 296.2 +/- 47.5 mu m in the non-proptosis group, and 288.3 +/- 55.1 mu m in the control group. There were no statistically significant differences among the groups with respect to choroidal thickness measurements (p>0.05). Conclusion: No significant difference in choroidal thickness was detected between Graves' patients with and without proptosis and the controls. There was no effect of clinical activation on choroidal thickness.eninfo:eu-repo/semantics/openAccessGraves' ophthalmopathychoroidal thicknessoptical coherence tomographyproptosisArticle50422122710.4274/tjo.galenos.2020.9741532854466WOS:000563088000006N/A